| Naslov: | Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program |
|---|
| Avtorji: | ID Illini, Oliver (Avtor)
ID Hochmair, Maximilian J (Avtor)
ID Fabikan, Hannah (Avtor)
ID Weinlinger, Christoph (Avtor)
ID Tufman, Amanda (Avtor)
ID Swalduz, Aurélie (Avtor)
ID Lamberg, Kristina (Avtor)
ID Hashemi, Sayed M. S. (Avtor)
ID Huemer, Florian (Avtor)
ID Vikström, Anders (Avtor)
ID Mohorčič, Katja, Klinika Golnik (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (777,25 KB)
MD5: 4E4A25935572544E10543B5761550F3C
PDF - Priloga, prenos (108,37 KB)
MD5: FEC0A24230BF6F365D92D0FF838F908C
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusio-%positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naïve, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n=8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade >/=3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated. |
|---|
| Ključne besede: | non-small cell lung carcinoma -- drug therapy -- genetics, molecular targeted therapy, real-world data, selpercatinib, targeted therapy, tyrosine kinase inhibitor |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Kraj izida: | Velika Britanija |
|---|
| Založnik: | Sage Journals |
|---|
| Leto izida: | 2021 |
|---|
| Št. strani: | str. 1-17 |
|---|
| Številčenje: | Vol. 13 |
|---|
| PID: | 20.500.12556/DiRROS-14130  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 1758-8359 |
|---|
| DOI: | 10.1177/17588359211019675 |
|---|
| COBISS.SI-ID: | 66935555 |
|---|
| Avtorske pravice: | © The Author(s), 2021. |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Soavtorica iz Slovenije: Katja Mohorčič;
Opis vira z dne 14. 6. 2021;
|
|---|
| Datum objave v DiRROS: | 16.06.2021 |
|---|
| Število ogledov: | 1760 |
|---|
| Število prenosov: | 958 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
